Gene Therapy Lyfgenia denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for gene therapy lyfgenia are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Aetna Prior Authorization Denial for Lyfgenia — Why It Happens and How to Appeal

Lyfgenia (lovotibeglogene autotemcel) is an FDA-approved one-time gene therapy for sickle cell disease. Aetna requires prior authorization (PA) before approving coverage for this therapy. A PA denial — whether for incomplete documentation, failure to address every clinical criterion in Aetna's Clinical Policy Bulletin, or an administrative gap in the submission — is not final. You have a right to appeal, and most PA denials for gene therapy are resolved on appeal when the documentation package is complete and precisely mapped to the policy.

## Why Prior Authorization Denials Happen for Gene Therapy

Aetna's PA reviewers check each submitted record against every requirement in the applicable Clinical Policy Bulletin (CPB) for Lyfgenia. The most common reasons for initial PA denial include: diagnostic records that document a diagnosis but do not describe disease severity in terms the policy requires; prior treatment records that list medications but do not document clinical outcomes or failure; specialist letters that are general rather than criterion-specific; or the PA being submitted by an office that is not the treating gene therapy center. Each of these gaps can be addressed on appeal.

## Federal Appeal Framework

• Internal appeal: File within 180 days of denial. Aetna must respond within 30 days (standard) or 72 hours (expedited/urgent).
• External review (ACA §2719): After final internal denial, request independent external review — typically within approximately 4 months of the denial. IROs apply independent clinical standards and are not bound by Aetna's CPB.
• ERISA §503: Employer-sponsored plan members have federally guaranteed full-and-fair review rights.
• Expedited review: Available when delay would seriously jeopardize health; request in writing and document the clinical urgency.

## Documentation to Gather

1. Complete diagnostic records: Records confirming sickle cell disease, including genetic/lab confirmation and chart documentation of disease severity — hospitalization frequency, vaso-occlusive events, transfusion dependence, or other objective disease burden measures as documented by your care team. 2. Dated prior treatment history: For every prior disease-modifying or supportive therapy, provide start/end dates, dose adequacy confirmation, and documented clinical outcome or reason for change. Aetna's CPB typically specifies what constitutes an adequate prior therapy trial. 3. Criterion-specific prescriber letter: Your treating hematologist or gene therapy program physician should write a letter that identifies Aetna's CPB for Lyfgenia by name, addresses each numbered criterion in sequence, and cites specific chart data for each. 4. Gene therapy center credentials: Documentation confirming the treating program's qualifications if Aetna's CPB requires an accredited or recognized center. 5. FDA prescribing label: Attach to confirm the indication and single-administration nature of the therapy.

## Criteria-Mapping Structure

Obtain the full text of Aetna's current CPB for Lyfgenia. For each criterion listed:

| Aetna CPB Criterion | Chart Evidence | Document Source | |---|---|---| | Confirmed diagnosis and indication | Genetic/lab confirmation | Lab records, specialist notes | | Documented disease severity | Clinical severity measures from chart | Hospitalization records, specialist notes | | Prior therapy with documented outcomes | Dated treatment history + outcomes | Prescriber letter + pharmacy records | | Prescriber/center qualifications | Treating hematologist credentials; program accreditation | Program documentation |

A PA appeal that reproduces Aetna's CPB criteria in a table and fills each row with specific chart data and document references is the most effective format. Ask your gene therapy center's patient access team to assist — they routinely support PA appeals for this class of therapy.